EFFICIENCY OF FELODIPINE AND TREATMENT COMPLIANCE OF OUTPATIENT HYPERTENSIVE PATIENTS


如何引用文章

全文:

详细

The authors have studied clinical efficacy of felodip (Felodip, TEVA) in patients with hypertension and analyzed factors influencing adherence to therapy in real-world outpatient practice. The study enrolled 5474 patients with arterial hypertension from 84 clinics in Moscow. According the results of Moriski - Green test on the first visit, patients were divided into 2 groups - first group with low adherence to treatment (LAT), and the second - with a high adherence to treatment. All patients received felodipine during 8 weeks. Among patients completed the study, over 98% of patients have reached the target blood pressure levels or decreased it by more than 20 and 10 mm Hg (systolic and diastolic, respectively). Improvement of quality of life, more pronounced in the LAT group, was observed. Male gender, older age is associated with lower adherence to therapy. By contrast, presence of home tonometer, coronary heart disease and diabetes mellitus are associated with higher adherence. The including of drug in reimbursement drug list is not independent and crucial factor for improvement of treatment compliance.

参考

  1. Тимофеева Т.Н., Деев А.Д., Шальнова С.А. и др. Аналитическая справка об эпидемиологической ситуации по АГ в 2008 году и ее динамике с 2003 по 2008 год по трем проведенным мониторингам. http://www.gnicpm.ru
  2. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295(2):180-9.
  3. Fletcher A. Quality of life in the management of hypertension. Clin Exp Hypertens 1999;21:961-72.
  4. Хохлов А.Л., Лисенкова Л.А., Раков А.А. Анализ факторов, определяющих приверженность к антигипертензивной терапии // Качественная клиническая практика 2003. № 4. C. 59-66.
  5. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007;25:1105-87.
  6. Morisky DE, Green LW, Levine DM. Concurent and predictive validity of self-reported measure of medical adherence. Med Care 1986;24:67-73.
  7. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). М., 2004.
  8. ЭПОХА-АГ // Кардиология 2004. № 11. C. 50-55. Adherence to long-term therapy, evidence of action, World Health Organization, 2003. www.who.int
  9. Caro JJ, Jackson J, Speckman J, et al. Compliance as a function of initial choce of antihypertensive drug. Am J Hypertens 1997;10:141A(Abstract).
  10. Haynes BR, Sackett DL, Gibson ES, et al. Improvement of medical compliance in uncontrolled hypertension. Lancet 1976;i:1265-68.
  11. Vrijens B, Goethebeur E. Comparing compliance patterns between randomized treatments. Controlled clinical trials 1997;18:187-203.
  12. Mancia G, Seravalle G, Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists. Am J Hypertens 2003;16(12):1066-73.
  13. Wogen J, Kreilick CA, Livornese RC. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003;9(5):424-29.
  14. Котовская Ю.В., Багманова Н.Х., Мильто А.С. и др. Эффективность и переносимость антигипертензивной терапии, основанной на фелодипине, у больных артериальной гипертонией в условиях стационара // Кардиология 2004. № 3. C. 47-51.
  15. Waeber B, Burnier M, Brunner HR. How to improve adherence with prescribed treatment in hypertensive patients? J Cardiovasc Pharmacol 2000;36(3):23-26.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##